Radiotherapy and Immunotherapy, Combined Treatment for Unresectable Mucosal Melanoma with Vaginal Origin
Source abstract
Abstract
Gynecologic melanomas are uncommon and malignant mucosal melanomas with vaginal origin are extremely rare, treatment strategies are limited and extrapolated from those of cutaneous melanoma. A better understanding of the vulvovaginal melanoma’s biology and its risk factors is needed. Therapeutic strategies include surgery, systemic therapy and radiotherapy. For vulvovaginal melanoma, surgery is selected as the primary treatment. Immunotherapy and target treatment have recently enhanced the systemic therapy for cutaneous melanoma (CM). Immunotherapy and new target agents demonstrated a better survival of melanoma and might be considered as treatment of vulvovaginal melanoma. Radiotherapy is included in the therapeutic arsenal for mucosal melanoma and may be performed on selected patients who may receive concurrent checkpoints and inhibition neoadjuvant radiotherapy with the purpose of reducing morbidity and mortality.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cutaneous Melanoma Detection and Management · Immunotherapy and Immune Responses · CAR-T cell therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiotherapy, ‘St. Apostol Andrei’ Emergency Clinical Hospital, 800578 Galati, Romania
Clinical Department, Faculty of Medicine and Pharmacy, ‘Dunarea de Jos’ University, 800010 Galati, Romania
Research Center in the Field of Medical and Pharmaceutical Sciences, ReFORM-UDJ, ‘Dunarea de Jos’ University, 800010 Galati, Romania
Surgical Department, Faculty of Medicine and Pharmacy, ‘Dunarea de Jos’ University, 800010 Galati, Romania
‘St. Spiridon’ Hospital, 700111 Iași, Romania
Department of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, ‘Dunarea de Jos’ University, 800010 Galati, Romania
8th Department, Faculty of Medicine, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania
References (37)
Show source-provided references
1. Anko, M., Kobayashi, Y., Banno, K., and Aoki, D. (2021). Current Status and Prospects of Immunotherapy for Gynecologic Melanoma. J. Pers. Med., 11.10.3390/jpm11050403 ↗
2. Melanoma of the Lower Genital Tract: Prognostic Factors and Treatment Modalities10.1016/j.ygyno.2018.04.562 ↗
3. Dika, E., Lambertini, M., Pellegrini, C., Veronesi, G., Melotti, B., Riefolo, M., Sperandi, F., Patrizi, A., Ricci, C., and Mussi, M. (2021). Cutaneous and Mucosal Melanomas of Uncommon Sites: Where Do We Stand Now?. J. Clin. Med., 10.10.3390/jcm10030478 ↗
4. (2022, April 02). Melanoma Incidence and Mortality, United States 2012–2016. US Cancer Statistics Data Briefs, Available online: https://www.cdc.gov/cancer/uscs/about/data-briefs/no9-melanoma-incidence-mortality-UnitedStates-2012-2016.htm.
5. (2022, February 06). Melanoma: Cutaneous. Guidelines. Available online: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf.
6. Management of vulvar and vaginal melanomas: Current and future strategies10.14694/EdBook_AM.2014.34.e277 ↗
7. Primary malignant melanoma of the vagina10.1097/AOG.0b013e3181fb8045 ↗
8. St Clair, C.M., Wethington, S.L., and Eaton, A.A. (2013, January 9–12). Vulvar and vaginal melanoma—A single institutional experience 1995–2012. Proceedings of the 44th Annual Meeting on Women’s Cancer, Los Angeles, CA, USA.
9. Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract10.1016/j.gore.2016.04.001 ↗
10. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline10.1016/j.ejca.2009.10.032 ↗
11. Distinct sets of genetic alterations in melanoma10.1056/NEJMoa050092 ↗
12. Somatic activation of KIT in distinct subtypes of melanoma10.1200/JCO.2006.06.2984 ↗
13. The Natural History and Patterns of Metastases from Mucosal Melanoma: An Analysis of 706 Prospectively-Followed Patients10.1093/annonc/mdw694 ↗
14. Mutation Scanning of BRAF, NRAS, KIT, and GNAQ/ GNA11 in Oral Mucosal Melanoma: A Study of 57 Cases10.1111/jop.12358 ↗
15. Landscape of Genomic Alterations (GA) and Tumor Mutational Burden (TMB) in Different Metastatic Melanoma (MM) Subtypes10.1200/JCO.2017.35.15_suppl.9536 ↗
16. Efficacy and Safety of Nivolumab Alone or in Combination with Ipilimumab in Patients with Mucosal Melanoma: A Pooled Analysis10.1200/JCO.2016.67.9258 ↗
17. Progressing Vulvar Melanoma Caused by Instability in c-KIT Juxtamembrane Domain: A Case Report and Review of Literature10.3390/curroncol29050254 ↗
18. Clinical, histological and therapeutical aspects in the management of uterine and extrauterine stromal sarcomas: Case reports10.3892/etm.2021.10891 ↗
19. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline—Update 201210.1016/j.ejca.2012.06.013 ↗
20. A randomized phase III trial of VH fıbrin sealant to reduce lymphedema after inguinal lymph node dissection: A Gynecologic Oncology Group study10.1016/j.ygyno.2008.03.005 ↗
21. Cutaneous and Inguinal Lymph Nodes Metastases Disseminated from an Endometrial Serous Carcinoma—Case Report and Literature Review10.21614/chirurgia.116.1.109 ↗
22. Improved survival with vemurafenib in melanoma with BRAF V600E mutation10.1056/NEJMoa1103782 ↗
23. Kuske, M., Haist, M., Jung, T., Grabbe, S., and Bros, M. (2022). Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?. Cancers, 14.10.3390/cancers14071710 ↗
24. Antitumour Activity of Pembrolizumab in Advanced Mucosal Melanoma: A Post-Hoc Analysis of KEYNOTE-001, 002, 00610.1038/s41416-018-0207-6 ↗
25. Safety and Efficacy of Nivolumab in Patients with Rare Melanoma Subtypes who Progressed on or after Ipilimumab Treatment: A Single-Arm, Open-Label, Phase II Study (CheckMate 172)10.1016/j.ejca.2019.07.010 ↗
26. Primary Malignant Melanoma of the Uterine Cervix or Vagina Which Were Successfully Treated with Nivolumab10.1111/jog.14136 ↗
27. Primary Malignant Melanoma of Vagina
28. Inoue, K., Tsubamoto, H., Isono-Nakata, R., Sakata, K., and Nakagomi, N. (2018). Itraconazole Treatment of Primary Malignant Melanoma of the Vagina Evaluated Using Positron Emission Tomography and Tissue cDNA Microarray: A Case Report. BMC Cancer, 18.10.1186/s12885-018-4520-5 ↗
29. Radiotherapy for Melanoma: More than DNA Damage10.1155/2019/9435389 ↗
30. Immunologic correlates of the abscopal effect in a patient with melanoma10.1056/NEJMoa1112824 ↗
31. Localized Synchrotron Irradiation of Mouse Skin Induces Persistent Systemic Genotoxic and Immune Responses10.1158/0008-5472.CAN-17-1066 ↗
32. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect10.1016/j.it.2018.06.001 ↗
33. Immunotherapy and radiotherapy in melanoma: A multidisciplinary comprehensive review
34. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab10.1007/s00415-012-6488-4 ↗
35. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases10.1093/neuonc/nov093 ↗
36. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment10.1016/j.ijrobp.2015.01.004 ↗
37. Ipilimumab and radiation therapy for melanoma brain metastases10.1002/cam4.140 ↗